Eli Lilly and Company's icon
Eli Lilly and Company

@immunitrack.com

Lilly is a medicine company turning science into healing to make life better for people around the world.

πŸ“’

Find anything inaccurate?

If you spot any mistakes on this brand profile, report to us.

Banner

Brand Logos

View all
Eli Lilly and Company's logos

Logo

SVG

Eli Lilly and Company's logos

Icon

PNG

About

Description

Immunitrack is a leading brand that offers a comprehensive product and service pipeline to optimize immunogenicity assessments during drug development. They also provide a wide range of reagents to monitor CD8 and CD4 T cell responses in patients during early research and clinical trials. With their expertise in Major Histocompatibility Complex (MHC), Immunitrack specializes in the manufacture and application of MHC I and II molecules and peptides, allowing for accurate study of MHC epitope binding through their proprietary NeoScreen platform.


This platform enables researchers to select and study neo-epitopes for personalized cancer vaccine development in the field of immuno-oncology. It also supports the selection of immunogenic epitopes from viral and bacterial targets for vaccine development. Additionally, Immunitrack offers de-immunization services to reduce the risk of anti-drug antibody development by identifying and removing CD4 T cell epitopes in candidate biologics.


They also provide reagents such as MHC tetramers and peptides to detect and quantify patient immune cells with specificity towards a given antigen. With their unique NeoScreen platform and expertise in MHC/epitope binding assays, Immunitrack offers researchers a scalable and accurate high-throughput platform to screen (neo-)epitopes for affinity and stability. This helps in the selection and progress of the best candidates through therapeutic development.


Founded in 2013, Immunitrack has a strong history of expertise in the field and is committed to providing tailor-made technology and reagents to the pharmaceutical industry and research community. Their mission is to support the selection or redesign of drug candidates during early R&D and to monitor the effects of lead drug candidates on patient immune responses. The management team at Immunitrack includes Karin Absalonsen as Chairman of the Board, Sune Justensen as Chief Scientific Officer, and Stephan Thorgrimsen as Chief Executive Officer.


They are supported by scientific advisors Frederik Bagger and Dr. Derin Keskin, who bring extensive knowledge and experience in their respective fields. For more information and to contact Immunitrack, visit their website or reach out to their dedicated customer service team

Read more...

Company Type

Privately Held

Company Size

11-50

Year Founded

2013

Brand collections

View all

Logos

Colors

Fonts

Images